Here's something I find myself wishing more women knew: osteoporosis doesn't appear out of nowhere in your late 70s. The changes that eventually lead to a fractured hip or a collapsed vertebra begin much, much earlier — quietly, during the menopause transition, years before most women ever have a bone density scan. The good news? We have real tools to protect the skeleton. We just need to know when to start paying attention.
When Does Bone Loss Actually Begin?
This is where the research gets genuinely eye-opening. We tend to anchor bone loss to chronological age, but the more important clock is biological — specifically, where a woman is in relation to her final menstrual period.
One of the most illuminating studies on this is the SWAN study — the Study of Women's Health Across the Nation — which followed a diverse group of women through the menopause transition and tracked their bone mineral density (BMD) over time. What the researchers found was striking: measurable bone loss at the lumbar spine and femoral neck began approximately one year before the final menstrual period. Loss then slowed about two years after that final period — but it didn't stop.
Here's the number that really lands: over a 10-year observation window, the lumbar spine lost about 10.6% of bone mineral density. Of that, roughly 7.38% — about 70% of the entire decade's loss — occurred within just a three-year window around the final menstrual period. That is a remarkable concentration of bone loss into a very short period of time.
Approximately 70% of a decade's worth of spine bone loss happened in just three years around the final menstrual period. That window matters enormously.
Rates vary — some women lose roughly 1–2% of BMD per year during this period of rapid change, though the actual figure depends on the skeletal site, timing, and individual factors like body weight and ethnicity. The SWAN investigators found that BMI and race/ethnicity both influenced bone-loss trajectories. So no, we can't assume every woman loses bone at the same rate just because she's the same age.
The practical implication here is important: waiting until several years after menopause to think about bone health means potentially missing a critical window for assessment and action.
Why Estrogen Matters So Much for Bone
To understand why the menopause transition is such a turning point for bone, it helps to understand what estrogen is doing in the first place. Estrogen suppresses bone resorption — the process by which osteoclasts (cells that break down bone tissue) do their work. It also supports osteoblasts, the cells that build new bone. When estrogen levels fall during menopause, resorption accelerates. If bone formation can't keep up, overall bone mass declines.
The 2021 Position Statement from the North American Menopause Society — a comprehensive review of the evidence on osteoporosis screening, prevention, and treatment — makes clear that estrogen deficiency is a central driver of postmenopausal bone loss, but also that we have multiple ways to address it. That balance between estrogen's role and the available alternatives is really the heart of the conversation.
Does Hormone Therapy Actually Protect Bone?
Yes — and the evidence here is solid. The PEPI trial (Postmenopausal Estrogen/Progestin Interventions trial) was a randomized study that looked at different hormone therapy regimens in postmenopausal women. It demonstrated that hormone therapy preserved or increased BMD compared with placebo — which is meaningful in itself.
But even more compelling is the fracture data from the Women's Health Initiative (WHI). In the WHI trial using conjugated equine estrogen plus medroxyprogesterone acetate, women receiving hormone therapy had:
- Approximately 33% lower relative risk of hip fracture compared to placebo
- Approximately 24% lower relative risk of total fractures compared to placebo
These are relative risk reductions, which means the absolute benefit for any individual woman depends on her underlying fracture risk. But the direction of the evidence is clear: hormone therapy reduces fractures, not just DXA numbers. And it's worth knowing that certain estrogen-containing menopausal hormone therapy products have carried an FDA-approved indication for the prevention of postmenopausal osteoporosis for many years — this isn't a new idea.
Of course, hormone therapy isn't right for every woman. Individual medical history, age, contraindications, and personal preferences all shape the decision. This is exactly the kind of conversation to have with a healthcare provider who knows your full picture.
What Happens to Bone When You Stop Hormone Therapy?
This is a question I don't think gets nearly enough attention in clinical conversations — and the research is genuinely important here.
The PEPI Safety Follow-up Study looked at what happened to bone density after women discontinued hormone therapy. Among women who had taken hormone therapy for three years and then stopped, bone loss resumed at approximately:
- −1.01% per year at the hip
- −1.04% per year at the spine
Importantly, these post-discontinuation rates were not significantly different from those seen in women who had never taken hormone therapy. In other words, hormone therapy protects bone while you're taking it, but that protection doesn't necessarily persist indefinitely after stopping. The skeleton doesn't bank the benefit.
Can Another Medication Step In?
This is where it gets encouraging. A randomized controlled trial by Ascott-Evans and colleagues looked at women with low BMD who had recently stopped hormone therapy. Half received alendronate (a bisphosphonate, sold as Fosamax), half received placebo, and both groups were followed for 12 months. The results after one year were striking:
- Alendronate group: lumbar spine BMD increased by +2.3%
- Placebo group: lumbar spine BMD decreased by −3.2%
- The difference between the two groups: 5.5 percentage points
This tells us something really practical: for women who stop hormone therapy and are losing bone as a result, there are bone-specific medications — bisphosphonates being one category — that can meaningfully intervene. The transition off hormone therapy doesn't have to mean unmanaged bone loss.
The Bigger Picture: Tools We Actually Have
The reason I find this area of medicine so worth understanding is that it is genuinely actionable. Bone loss during the menopause transition isn't invisible and it isn't inevitable in the sense of being unaddressable. We have:
- Screening tools — DXA scans to measure bone mineral density
- Risk assessment frameworks — like FRAX, which estimates 10-year fracture probability
- Hormone therapy — FDA-approved for osteoporosis prevention in appropriate candidates
- Bisphosphonates and other bone medications — effective alternatives or follow-on options
- Lifestyle measures — weight-bearing exercise, adequate calcium and vitamin D, avoiding smoking and excess alcohol — all of which contribute to skeletal health
The goal isn't to alarm anyone. It's to make sure that bone health becomes part of the menopause conversation early — not something that surfaces for the first time after a fracture.
A Practical Takeaway
If you're in perimenopause, approaching menopause, or have already passed your final menstrual period, bone health is worth putting on your radar now. Ask your doctor about your fracture risk, whether a DXA scan is appropriate for you, and what your options look like — including what happens to your bones if you're currently on hormone therapy and considering stopping. These are solvable problems. The research gives us a clear picture of when bone loss happens, how much it matters, and what can be done. That's actually a hopeful story — as long as we're telling it early enough.
This article is for informational purposes only and does not constitute medical advice. Please consult a qualified healthcare professional for guidance specific to your health history and needs.